Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial

Arthritis Research and Therapy

Volumn 17, Issue 1, 2015, Pages

  Manders, Sofie H M ^a   Kievit, Wietske ^a   Adang, Eddy ^a   Brus, Herman L ^b   Moens, Hein J Bernelot ^c   Hartkamp, Andre ^d   Hendriks, Lidy ^e   Brouwer, Elisabeth ^f   Visser, Henk ^g   Vonkeman, Harald E ^h   Hendrikx, Jos ^a   Jansen, Tim L ^a   Westhovens, Rene ^i,j   van de Laar, Mart A F J ^h   van Riel, Piet L C M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Microvida Laboratory for Medical Microbiology and Immunology   (Netherlands)

^c TWENTEBORG HOSPITAL   (Netherlands)

^d JEROEN BOSCH HOSPITAL   (Netherlands)

^e MEDICAL CENTER LEEUWARDEN   (Netherlands)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g RIJNSTATE HOSPITAL   (Netherlands)

^h MEDISCH SPECTRUM TWENTE   (Netherlands)

ⁱ UNIVERSITY OF LEUVEN   (Belgium)

^j UNIVERSITY HOSPITALS LEUVEN   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR;

ABNORMAL LABORATORY RESULT; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DAS28; DIZZINESS; DRUG TREATMENT FAILURE; EQ 5D SCORE; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH CARE COST; HUMAN; INFECTION; INFLUENZA; LEUKOPENIA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM; OUTCOME ASSESSMENT; PSYCHOSIS; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SHORT FORM 36; SKIN MANIFESTATION; SURVIVAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG RESISTANCE; ECONOMICS; TREATMENT OUTCOME;

ABATACEPT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; RITUXIMAB; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84929414384     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-015-0630-5     Document Type: Article

References (47)

1. Jobanputra P, Maggs F, Deeming A, Carruthers D, Rankin E, Jordan AC, et al. A randomised efficacy and discontinuation study of etanercept versus adalimumab (RED SEA) for rheumatoid arthritis: a pragmatic, unblinded, non-inferiority study of first TNF inhibitor use: outcomes over 2 years. BMJ Open. 2012;2:e001395.
2. Hyrich KL, Watson KD, Lunt M, Symmons DPM, British Society for Rheumatology Biologics Register (BSRBR). Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008. Rheumatology. 2011;50:117-23.
3. Kievit W, Fransen J, Oerlemans AJ, Kuper HH, van der Laar MA, de Rooij DJ, et al. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Ann Rheum Dis. 2007;66:1473-8.
4. Haraoui B, Keystone EC, Thorne JC, Pope JE, Chen I, Asare CG, et al. Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J Rheumatol. 2004;31:2356-9.
5. Nikas SN, Voulgari PV, Alamanos Y, Papadopoulos CG, Venetsanopoulou AI, Georgiadis AN, et al. Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study. Ann Rheum Dis. 2006;65:257-60.
6. Wick MC, Ernestam S, Lindblad S, Bratt J, Klareskog L, van Vollenhoven RF. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital. Scand J Rheumatol. 2005;34:353-8.
7. Cohen G, Courvoisier N, Cohen JD, Zaltni S, Sany J, Combe B. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2005;23:795-800.
8. Hjardem E, Østergaard M, Pødenphant J, Tarp U, Andersen LS, Bing J, et al. Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor α inhibitor? Ann Rheum Dis. 2007;66:1184-9.
9. Buch MH, Bingham SJ, Bejarano V, Bryer D, White J, Reece R, et al. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept. Arthritis Rheum. 2007;57:448-53.
10. Blom M, Kievit W, Donders AR, den Broeder AA, Straten VH, Kuper I, et al. Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis. J Rheumatol. 2011;38:2355-61.
11. Genovese MC. Biologic therapies in clinical development for the treatment of rheumatoid arthritis. J Clin Rheumatol. 2005;11:S45-54.
12. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793-806.
13. Burmester GR, Feist E, Kellner H, Braun J, Iking-Konert C, Rubbert-Roth A. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis. 2011;70:755-9.
14. Schoels M, Aletaha D, Smolen JS, Wong JB. Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. Ann Rheum Dis. 2012;71:1303-8.
15. Salliot C, Finckh A, Katchamart W, Lu Y, Sun Y, Bombardier C, et al. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann Rheum Dis. 2011;70:266-71. A published erratum appears in Ann Rheum Dis. 2011;70:560.
16. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44-8.
17. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol. 1982;9:789-93.
18. Ware Jr JE, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-83.
19. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 2nd ed. New York: Oxford University press; 1997.
20. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33:337-43.
21. EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199-208.
22. Care Institute Netherlands. Medication costs website. https://www.medicijnkosten.nl/ . Accessed 21 Apr 2015.
23. Prevoo MLL, van Gestel AM, van 't Hof MA, van Rijswijk MH, van de Putte LBA, van Riel PLCM. Remission in a prospective study of patients with rheumatoid arthritis: American Rheumatism Association preliminary remission criteria in relation to the Disease Activity Score. Br J Rheumatol. 1996;35:1101-5.
24. Borm GF, Fransen J, Lemmens WA. A simple sample size formula for analysis of covariance in randomized clinical trials. J Clin Epidemiol. 2007;60:1234-8.
25. Welsing PM, van Riel PL. The Nijmegen inception cohort of early rheumatoid arthritis. J Rheumatol Suppl. 2004;69:14-21.
26. Zhong B. How to calculate sample size in randomized controlled trial? J Thorac Dis. 2009;1:51-4.
27. Cost-effectiveness of new medicines (Mabthera and Orencia) compared to a second TNF blocking medicine, for patients with inadequate effect of a first TNF blocking medicine. Dutch Trial Register number NTR1605. http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=1605 . Accessed 21 Apr 2015.
28. Moons KG, Donders RA, Stijnen T, Harrell Jr FE. Using the outcome for imputation of missing predictor values was preferred. J Clin Epidemiol. 2006;59:1092-101.
29. Groenwold RH, White IR, Donders AR, Carpenter JR, Altman DG, Moons KG. Missing covariate data in clinical research: when and when not to use the missing-indicator method for analysis. CMAJ. 2012;184:1265-9.
30. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 1996;39:34-40.
31. Harrold LR, Reed GW, Kremer JM, Curtis JR, Solomon DH, Hochberg MC, et al. The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor. Ann Rheum Dis. 2015;74:430-6.
32. Finckh A, Ciurea A, Brulhart L, Möller B, Walker UA, Courvoisier D, et al. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis. 2010;69:387-93.
33. Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health Technol Assess. 2011;15:1-278.
34. Hallinen TA, Soini EJ, Eklund K, Puolakka K. Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting. Rheumatology. 2010;49:767-77.
35. Athanasakis K, Petrakis I, Kyriopoulos J. Investigating the value of abatacept in the treatment of rheumatoid arthritis: a systematic review of cost-effectiveness studies. ISRN Rheumatol. 2013;2013:256871.
36. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Clin Epidemiol. 2009;62:499-505.
37. Hotopf M. The pragmatic randomised controlled trial. Adv Psychiatr Treat. 2002;8:326-33.
38. Zink A, Strangfeld A, Schneider M, Herzer P, Hierse F, Stoyanova-Scholz M, et al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum. 2006;54:3399-407.
39. Bergman GJ, Hochberg MC, Boers M, Wintfeld N, Kielhorn A, Jansen JP. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum. 2010;39:425-41.
40. Woodrick R, Ruderman EM. Anti-interleukin-6 therapy in rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2010;68:211-7.
41. Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis. 2011;70:1575-80.
42. Maneiro RJ, Salgado E, Carmona L, Gomez-Reino JJ. Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: systematic review and meta-analysis. Semin Arthritis Rheum. 2013;43:9-17.
43. Daïen CI, Morel J. Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine. Mediators Inflamm. 2014;2014:386148.
44. Wells AF, Jodat N, Schiff M. A critical evaluation of the role of subcutaneous abatacept in the treatment of rheumatoid arthritis: patient considerations. Biologics. 2014;8:41-55.
45. Aaltonen KJ, Joensuu JT, Virkki L, Sokka T, Aronen P, Relas H, et al. Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy. J Rheumatol. 2015;42:372-8.
46. van Vollenhoven RF, Emery P, Bingham 3rd CO, Keystone EC, Fleischmann RM, Furst DE, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72:1496-502.
47. Bredemeier M, de Oliveira FK, Rocha CM. Low- versus high-dose rituximab for rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res. 2014;66:228-35.